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Objectives: Analyze the oncologic and func-
tional outcomes in patients affected by low
risk prostate cancer underwent prostate cryotherapy.
Materiasl and methods: It’s a prospective tricentric study of
434 patients treated with prostate cryoablation for low risk
prostate cancer. By low risk we refer to the D'Amico’s risk
classification. Two cycles of freezing/thawing are run for each
patient following the technique described by Onik.
Results: For the 434 patients, the median age was 66 years
with a standard deviation of ± 6.68, the average PSA was 6.17
ng/d/L, the median 5.55 with a standard deviation of ± 2.13,
the mean prostate volume was 35.59 cc, the median 34.00 cc,
with a standard deviation of ± 7.89. Biochemical failure
occurred in 67 patients (15.4%). Pre-operative erectile function
in men was distributed as follows: severe in 95 patients
(19.2%), moderate in 95 (19.2%), medium-moderate in 180
(36.4%), mild in 92 (18.6%), with no dysfunction in 32 (6.5%)
patients. Post-operative erectile function, measured 1 month
after cryotherapy, was distributed as follows: severe in 321
(65%) patients, moderate in 69 (14%), medium-moderate in 79
(16%), mild in 23 (4.7%), and no dysfunction in only 2 patients
(0.4%). Post-operative erectile function after 3 months was dis-
tributed as follows: severe in 233 (47.2%) patients, moderate
in 66 (13.4%), medium-moderate in 122 (24.7%), mild in 65
(13.2%), and no dysfunction in 8 patients (1.6%). Urinary
incontinence was present in 21 patients (4.8%) after 3 months
while it dropped to 13 patients (2.9%) after 6 months.
Conclusions: Cryotherapy in the treatment of prostate cancer
remains a viable alternative. The availability of new cry-
oprobes and the use of new diagnostic means such as fusion
magnetic resonance will make this more precise and more
effective method.
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Currently there are many different options for treatments
of prostate cancer, particularly for the low risk variety
from D'Amico’s risk classification (2).
According to the latest EAU guidelines there are different
types of standard treatments for low risk prostate cancer.
In recent years, with the aim of reducing the risk of
overtreatment in this subgroup of patients, two conser-
vative management strategies have been proposed:
watchful waiting and active surveillance (3).
Surgical treatment of PCa consists of the radical prosta-
tectomy (RP). In low risk patients the gold standard of
care is the nerve sparing technique. The goal of surgery
is to eradicate the disease by preserving continence and
sexual potency when possible (4). Pelvic lymph node dis-
section (LND) is not required for low-risk tumors because
the risk of positive lymph nodes does not exceed 5%,
according to Briganti’s nomograms (5). Radiotherapy for
prostate cancer is an important and safe alternative to
surgery and is the only form of curative treatment (6-7).
For the treatment of clinically localized prostate cancer
new therapeutic approaches have emerged as alternative
therapeutic options: defined focal therapies that include
two methods, the HIFU (high-intensity focused ultra-
sound) and Cryotherapy (CSAP) (8-9).
The use of cryosurgery has been enhanced thanks to the
introduction of a modern percutaneous approach using
trans-rectal ultrasound probe introduced by Onik et al. in
1993 (8). In 2008 the AUA’s best practice statement on
cryosurgery affirmed that cryosurgery is an option for
patients with an organ confined disease (10).
The aim of this study is to investigate the oncological and
functional outcomes in patients affected by low-risk
prostate cancer.
MATERIALS AND METHODS
Our is a prospective tricentric study of 434 patients
treated with prostate cryoablation for low risk prostate
cancer. By low risk we refer to the D'Amico risk classifi-
DOI: 10.4081/aiua.2017.2.97
INTRODUCTION
In the era of the PSA screening the detected rate of
prostate cancer has dramatically increased (1).
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cation of clinical stage (< T2a, PSA levels < 10.0 ng/mL,
and a Gleason score ≤ 6). All patients were operated on
using the same surgical technique, performed by the
same surgeon in 80% of cases. The surgery was per-
formed under general anesthesia. 
Patient preparation includes cleansing with enema and
broad spectrum antibiotic prophylaxis. The patient is in
the dorsal lithotomy position, in this way facilitating the
exposure of the perineum and the movements of the rec-
tal probe (Probe longitudinal biplane to 7.5 Hz). In all cases
the coaxial system Stryker Cryo/44 was used with cry-
oprobes of 2.4 mm in diameter, from six to eight in
number depending on prostate volume. Cryoablation
involves 2 cycles, one freezing and one cooling; respec-
tively exploiting cycles of pressurized gas, argon (300 bar
of pressure and -180°C) for the freezing cycle and heli-
um for the heating cycle (200 bar of pressure with -
180°C temperature exchange to 40°C in 30 seconds).
The temperature is monitored inside and outside of the
prostate. Thermal sensors, are positioned in the apex,
external sphincter, and neurovascolar bundle to the right
and to the left of the gland.
Hydrodistention of the rectal area prostate was performed
by injecting saline solution mixed with broad-spectrum
antibiotic in the Denonvilliers' fascia (Onik maneuver
band). Control cystoscopy is performed in order to ensure
integrity of the urethra, which is protected by means of an
FDA-approved continuous flow system with a pump
pressure of 4.5 bar, which puts blue methylene physio-
logical solution into circulation at 41°C and keeps adja-
cent tissues at a temperature of 38°C (11-14).
At each cryoablation two complete cycles of freezing/
thawing are run. Depending on prostate volume or on
prostates with a larger longitudinal diameter of 35 mm, a
third cycle with a distal displacement of 10 millimeters of
cryoprobes was necessary, in a maneuver referred to as
"pull back". The patients were discharged within 24 hours,
with a catheter in place for two weeks and were given anti-
inflammatory drugs for the pain (8).
Biochemical recurrence was determined according to the
Phoenix defined by ASTRO criteria as a rising PSA, above
the Nadir of more than 2 ng/mL (15).
Follow-up was carried out in hospital laboratories by
monitoring PSA level every month for the first three
months and then once every six months for a total of 54
months.
Statistical analysis
Statistical analysis was performed with Stata 14 software
by StataCorp, descriptive variables were analyzed using
mean, median, standard deviation, and a 95% confi-
dence interval (95% CI). The survival curves were
described using the Kaplan-Meier method. After making
the appropriate test for normality (Shapiro-Wilk test) to
validate if the assumptions underlying the model were
statistically satisfied. We applied the model of analysis of
variance in our sample. 
RESULTS
For the 434 patients, the median age was 66 years with a
standard deviation of ± 6.68, the average PSA was 6.17
ng/dL, the median 5.55 with a standard deviation of ±
2.13, the mean prostate volume was 35.59 cc, the median
34.00 cc, with a standard deviation of ± 7.89.
Biopsies performed on patients for pre-intervention of
disease diagnosis were conducted trans-rectally in 421
patients (97%), and trans-perineally in 13 patients (3%).
Biochemical failure occurred in 67 patients (15.4%)
(Figures 1-2).
The survival curve it’s shown in the Kaplan-Meier graph
(Figure 3).
The average hospital stay was for 1.89 days, with a medi-
an of 1 and a standard deviation of ± 1.48.
Figures 1-2. 
Box plot PSA/time.
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Pre-operative erectile function in men (Figure 4) was dis-
tributed as follows: severe in 95 patients (19.2%), mod-
erate in 95 (19.2%), medium-moderate in 180 (36.4%),
mild in 92 (18.6%), with no dysfunction in 32 (6.5%)
patients.
Post-operative erectile function, measured 1 month after
cryotherapy (Figure 4), was distributed as follows: severe
in 321 (65%) patients, moderate in 69 (14%), medium-
moderate in 79 (16%), mild in 23 (4.7%), and no dys-
function in only 2 patients (0.4%).
Post-operative erectile function (Figure 4) after 3 months
was distributed as follows: severe in 233 (47.2%) patients,
moderate in 66 (13.4%), medium-moderate in 122
(24.7%), mild in 65 (13.2%), and no dysfunction in 8
patients (1.6%). In 87% of cases (377 patients) two freeze
and thaw cycles were applied while three cycles were
applied in the remaining 13% of patients (57 patients)
due to the size and/or morphology of the prostate.
Number 4 needles were used in 68 patients (15.6%),
number 6 needles in 290 patients (67.4%), and number
8 needles were used in 73 patients (17%).
Urinary incontinence was present in 21 patients (4.8%)
after 3 months while it dropped to 13 patients (2.9%)
after 6 months.
Concerning complications:
• Perineal hematoma in 207 (47.6%), 
• LUTS in 149 patients (34.3%), 
• Scrotal hematoma in 119 patients (27.4%),
• Urinary tract infection in 44 patients (10%),
• Perineal pain in 38 patients (8.7%), 
• Scrotal edema in 33 patients (7.6%),
• Persistent hematuria was present in 22 patients (5%),
• Urinary fistula in 16 patients (3.6%),
• Urethral stricture in 14 patients (3.2%), 
• Hydronephrosis in only 1 patient (0.2%).
DISCUSSION
Cryotherapy for the treatment of prostate cancer is a tech-
nique that was originally introduced in 1960, but was
soon abandoned because of excessive morbidity (11-13).
The use of this therapeutic approach has increased with
its reintroduction by Onik et al. in 1993 thanks to the
introduction of a modern percutaneous approach with
the aid of a trans-rectal ultrasound probe (8).
The treatment itself has undergone an evolution over
decades of application in clinical practice; the develop-
ment of interventional radiology has improved cryogenic
technology and provided a better understanding of cry-
obiology (16-17).
The action mechanism of cryotherapy is complex. It
exerts its effect by: the induction of protein denaturation,
dehydration, rupture of the cell membrane due to expan-
sion of ice crystals, the transfer of water from the intra-
cellular side to extracellular spaces, vascular stasis, the
induction of apoptosis, increasing the concentration of
toxic substances at the intracellular level and finally
osmotic shock (8, 11-14).
Traditionally, supporters of cryotherapy as primary treat-
ment for prostate cancer have sustained that the procedure
offers advantages over conventional treatments, allowing a
non-invasive treatment of cancer in patients who are very
elderly or are suffering from multi-comorbidity and would
otherwise not be eligible candidates for traditional sur-
gery; in recent years refinement of the procedure has also
allowed an increase in effectiveness and safety.
Our data on survival free from biochemical recurrence
after a follow-up of 54 months proves that this proce-
dure produces efficacy rates that are highly competitive
with all other conventional forms of therapy recom-
mended by European and international guidelines;
above all with three-dimensional radiation therapy, con-
formational radiotherapy or brachytherapy. 
Our findings strongly indicate a need to expand the role
of cryoablation in clinical practice of prostate cancer
treatment. Head to head comparison with different
modalities of treatment for prostate cancer is affected by
several factors such as:
• the retrospective nature of the study, 
• the monocentric nature of most studies,
• the often non-uniform or standardized selection of
patients,
• the use of various dosing procedures and different
techniques conducted by different laboratories,
• variations, according to different classification criteria,
in the definition of biochemical failure.
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Figure 3. 
Kaplan-Meier curve.
Figure 4. 
Diagram IIEF-5 Pre operative; Post operative; After 3 months.
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As a result, there is no definitive oncological comparative
data. However, in a recent comparative study between
cryoablation and radiation therapy conducted on 244
patients no significant differences between the two
groups (76%) were found (15).
In another trial a PSA nadir of less than 0.4 ng/ml in 81%
of patients was shown without biochemical progression
for 12 months of study.
In another single-center study with 590 patients and a
mean follow-up of 7 years, the percentage of patients free
of biochemical recurrence was approximately 61% (16).
However, not all data in the literature support the idea
that cryotherapy and radiotherapy are equivalent, espe-
cially in high-risk patients.
UAE guidelines, compared with AUA guidelines, show a
substantial difference in classifying candidate patients for
cryotherapy; in fact, in Europe, the “model” patient
remains the low risk patient, whereas in the United
States the procedure has been extended to cases of high-
er risk, as long as the disease is organ-confined.
Another aspect to consider is the comparison with inva-
sive treatments such as radical prostatectomy. Gould et al.
have shown a lower incidence of biochemical recurrence
in patients who underwent cryotherapy compared to
radical prostatectomy. This study presents several biases
and was conducted on a small number of patients (18).
Active surveillance is one of the treatment options for
patients at low risk of prostate cancer.
Klotz et al. have analyzed patients ranging from T1c and
T2a, PSA < 10 ng/mL, Gleason score < 6, or PSA < 15
ng/mL for patients older than 70 years with Gleason < 7
(3 + 4) (19-20).
With an average follow-up of 6.8 years, survival at 10
years was 97.2%. For the 62% of patients who were still
in active surveillance, 30% underwent radical prostatec-
tomy; 10% preferred to switch to active treatment due to
a PSA doubling time < 3 years or an advancing Gleason
score. The collective survival varies from 70% to 100%.
Biochemical failure has occurred in 13% of patients
undergoing active surveillance (21).
More recently a number of radical prostatectomies for
low and intermediate risk patients demonstrated a per-
centage of PSA free survival from 60% to 65% and a can-
cer specific survival between 94% and 97% with a fol-
low-up of 53 to 153 months. For high risk patients bio-
chemical failure was 44% and 53% after 5 and 10 years
respectively (22).
In 2010 Donnelly et al. published a randomized article
that compared patients with localized prostate cancer
treated with ERBT versus cryotherapy. They demonstrat-
ed no significant difference between the two techniques
after 36 months in 244 patients with a mean follow-up
of 100 months. The was some progression of the disease
at 36 months in 23.9% of patients undergoing cryother-
apy and 23.7% in patients receiving radiotherapy. 
No difference was observed in the specific servival of the
disease.
In another article, Donnelly et al. have also compared rad-
ical surgery, ERBT and brachytherapy with the data of
cryotherapy in medium- and high-risk patients. The
interval free of biochemical recurrence for medium risk
patients was 37-97% for the radical prostatectomy, 26-
60% for the ERBT and 66-82% for the brachytherapy. In
high-risk patients the interval free of biochemical recur-
rence decreases to 16-61% in low-risk, 19-25% in the
ERBT, and 40-65% in brachytherapy (23).
With this data the authors concluded that cryotherapy
seems superior to EBRT for moderate and high risk
patients, and the data seemed comparable for medium-
high risk patients undergoing brachytherapy and radical
prostatectomy (15). In our series biochemical recurrence
occurred in 15.4%, with an incidence lower than many
previously published trials.
In 2008, Cohen et al. reported 370 patients with a mean
follow-up of 147 months and an interval free ofbio-
chemical recurrence in 80%, 74% and 46% respectively,
for low, intermediate and high risk patients (24).
In our study we assessed erectile function, giving the
patient the IIEF-5 test, we then evaluated the differences
between the various categories. From the graphs you can
see how classes with greater “movement” of patients
towards worse erectile function in absolute terms are the
patients with average to moderate dysfunction and slight
during the pre-operative assessment phase, passing to
the postoperative, respectively from 180 to 79 and 92 to
32, while patients with severe dysfunction increased
from 95 to 321 or from 19.2% to 65%.
Radiation therapy appears to have a lesser impact on
erectile function (25).
The percentage of maintained erectile function after var-
ious interventions was 0.76 after brachytherapy, 0.60
after brachytherapy + external beam irradiation, 0.55
after external irradiation only, 0.34 after nerve-sparing
radical prostatectomy and 0.25 after standard radical
prostatectomy. Selecting studies with a 2 year disease fol-
low-up (excluding brachytherapy), the percentage was
0.60, 0.52, 0.25 and 0.25 respectively (26).
In terms of quality of life, there are several studies that
compare cryotherapy as a treatment for a locally
advanced tumor. Patients treated with cryotherapy and
brachytherapy reported a higher score of urinary disor-
ders when compared with radical prostatectomy (27).
Since it was adopted, robotic prostatectomy has not
shown significant benefits in functional outcome com-
pared with the open approach. Ball et al. compared 719
patients treated with open, laparoscopic and a robotic
approach, as well as brachytherapy and cryotherapy (28).
Men treated with brachytherapy and cryotherapy were
older and had more co-morbidities. The analysis demon-
strated that cryotherapy has a negative impact on erectile
function with respect to brachytherapy, and that this
effect is reduced to 3 and 6 months, while the irritative
and obstructive symptoms were higher in brachythera-
py. In patients undergoing cryotherapy, worse sexual
outcomes were demonstrated than in other treatments,
but the baseline was also lower.
CONCLUSIONS
Cryotherapy in the treatment of PCa remains a viable
alternative to more invasive approaches. The availability
of new cryoprobes and the use of new diagnostic means
such as fusion magnetic resonance will make this more
precise and more effective method.
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